Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period

Minoru Takahashi, Yaron Ilan, Namita Roy Chowdhury, Jack Guida, Marshall Horwitz, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Injection of a recombinant adenovirus expressing human bilirubin-UGT1 (Ad-hBUGT1) (3 x 109 plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70% reduction of serum bilirubin levels. However, the effect was transient, and host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 108 pfu of Ad- hBUGT1 or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli β- galactosidase) into 1-3-day-old Gunn rats. Two subsequent injections (3 x 109 pfu) were given 56 and 112 days after the initial injection. Injection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pups (9 ± 1.3 mg/dl), followed by a gradual increase to 3.25 ± 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.

Original languageEnglish (US)
Pages (from-to)26536-26542
Number of pages7
JournalJournal of Biological Chemistry
Volume271
Issue number43
DOIs
StatePublished - 1996

Fingerprint

bilirubin glucuronoside glucuronosyltransferase
Gunn Rats
Viruses
Bilirubin
Adenoviridae
Rats
Injections
Galactosidases
Gene therapy
Lymphocytes
Neutralizing Antibodies
Escherichia coli
Serum
Human Adenoviruses
Humoral Immunity

ASJC Scopus subject areas

  • Biochemistry

Cite this

Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. / Takahashi, Minoru; Ilan, Yaron; Chowdhury, Namita Roy; Guida, Jack; Horwitz, Marshall; Roy-Chowdhury, Jayanta.

In: Journal of Biological Chemistry, Vol. 271, No. 43, 1996, p. 26536-26542.

Research output: Contribution to journalArticle

@article{6fa4240d55984a92ac6b47bda719119d,
title = "Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period",
abstract = "Injection of a recombinant adenovirus expressing human bilirubin-UGT1 (Ad-hBUGT1) (3 x 109 plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70{\%} reduction of serum bilirubin levels. However, the effect was transient, and host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 108 pfu of Ad- hBUGT1 or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli β- galactosidase) into 1-3-day-old Gunn rats. Two subsequent injections (3 x 109 pfu) were given 56 and 112 days after the initial injection. Injection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76{\%} of the levels in untreated pups (9 ± 1.3 mg/dl), followed by a gradual increase to 3.25 ± 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.",
author = "Minoru Takahashi and Yaron Ilan and Chowdhury, {Namita Roy} and Jack Guida and Marshall Horwitz and Jayanta Roy-Chowdhury",
year = "1996",
doi = "10.1074/jbc.271.43.26536",
language = "English (US)",
volume = "271",
pages = "26536--26542",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "43",

}

TY - JOUR

T1 - Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period

AU - Takahashi, Minoru

AU - Ilan, Yaron

AU - Chowdhury, Namita Roy

AU - Guida, Jack

AU - Horwitz, Marshall

AU - Roy-Chowdhury, Jayanta

PY - 1996

Y1 - 1996

N2 - Injection of a recombinant adenovirus expressing human bilirubin-UGT1 (Ad-hBUGT1) (3 x 109 plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70% reduction of serum bilirubin levels. However, the effect was transient, and host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 108 pfu of Ad- hBUGT1 or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli β- galactosidase) into 1-3-day-old Gunn rats. Two subsequent injections (3 x 109 pfu) were given 56 and 112 days after the initial injection. Injection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pups (9 ± 1.3 mg/dl), followed by a gradual increase to 3.25 ± 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.

AB - Injection of a recombinant adenovirus expressing human bilirubin-UGT1 (Ad-hBUGT1) (3 x 109 plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70% reduction of serum bilirubin levels. However, the effect was transient, and host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 108 pfu of Ad- hBUGT1 or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli β- galactosidase) into 1-3-day-old Gunn rats. Two subsequent injections (3 x 109 pfu) were given 56 and 112 days after the initial injection. Injection of Ad-BUGT1, but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pups (9 ± 1.3 mg/dl), followed by a gradual increase to 3.25 ± 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.

UR - http://www.scopus.com/inward/record.url?scp=0029970829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029970829&partnerID=8YFLogxK

U2 - 10.1074/jbc.271.43.26536

DO - 10.1074/jbc.271.43.26536

M3 - Article

C2 - 8900123

AN - SCOPUS:0029970829

VL - 271

SP - 26536

EP - 26542

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 43

ER -